425: SWK Holdings Merger with Runway Growth Finance Detailed

SWK Holdings Corporation outlines merger consideration with Runway Growth Finance Corp., including cash and stock components.

Summary

• SWK Holdings Corporation is merging with Runway Growth Finance Corp. (RWAY) in a transaction expected to close late 4Q25 to early 1Q26.
• The merger consideration for SWK shareholders includes both a cash component and a fixed $75.5 million book value of RWAY shares, subject to a 19.9% cap relative to RWAY's outstanding common stock.
• The cash component from RWAY is derived from SWK's NAV (48 hours prior to Close), adjusted for deferred tax assets, intangible assets, and SWK transaction expenses paid at Close, then reduced by the $75.5 million RWAY stock book value.
• An additional fixed cash payment of $9.0 million will be provided by RWAY's external manager, Runway Growth Capital LLC.
• As of June 30, 2025, RWAY's NAV per share was $13.66, implying approximately 5.527 million RWAY shares would be distributed (0.457 shares per SWK share).
• Based on RWAY's October 9, 2025 closing price of $9.82, the market value of the stock component was approximately $54.3 million ($4.49 per SWK share).
• The estimated total value per SWK share at market, based on 2Q25 figures and estimates, is approximately $17.10.
• The merger is expected to be a taxable event for SWK shareholders.
• RWAY will be required to offer to call SWK's bond at par due to the change of control.

Sentiment

Score: 7

Explanation: The merger provides a structured exit for SWK shareholders with a mix of cash and stock, offering liquidity and continued exposure. The deal structure is detailed, and an additional fixed cash payment from the manager adds certainty. However, the market value of the stock component is subject to RWAY's share price volatility, the transaction is taxable, and various risks inherent to mergers and the life science sector are present.

Positives

• Provides a clear exit strategy for SWK shareholders through a combination of cash and RWAY stock.
• Includes a fixed $9.0 million cash payment from RWAY's external manager, adding certainty to the cash consideration.
• SWK shareholders will receive continued exposure to the life science financing sector through RWAY stock.
• Cumulative net income generated by SWK between 2Q25 and Close is expected to positively impact the cash component, with 3Q25 benefiting from a $2.4 million Elutia payoff and gains in warrant book FMV.

Negatives

• The market value of the RWAY stock component is subject to fluctuations in RWAY's stock price.
• The final number of RWAY shares received by SWK shareholders will vary inversely with RWAY's NAV per share at Close.
• The merger is expected to be a taxable event for SWK shareholders, potentially incurring capital gains taxes.
• SWK will incur transaction expenses, estimated to be in the $5-7 million range, which will reduce the cash component of the consideration.

Risks

• Uncertainty regarding the ability of the parties to consummate the merger on the expected timeline, or at all.
• Risk that expected synergies and savings associated with the merger may not be fully realized.
• Inability to realize the anticipated benefits of the merger, including the expected elimination of certain expenses and costs.
• Potential impact of the merger on the depth of trading in Runway's shares of common stock post-closing.
• Possibility that any or all of the various conditions to the consummation of the merger may not be satisfied or waived.
• Risks related to diverting management's attention from ongoing business operations.
• Any potential termination of the merger agreement.
• Uncertainty regarding the future operating results and net investment income projections of the combined company.
• Challenges for Runway Growth Capital LLC and its affiliates to attract and retain highly talented professionals.
• Business prospects of the combined company and the prospects of its portfolio companies.
• The combined company may seek to incur additional financings, investments, and leverage in the future.
• Adequacy of the cash resources and working capital of the combined company.
• Risk that stockholder litigation in connection with the merger may result in significant costs of defense and liability.
• High degree of risk associated with the research and development of medical products within portfolio companies, with only a small number of programs resulting in commercialization.

Future Outlook

The combined company's future operating results and net investment income projections are subject to various factors. Runway Growth Capital LLC aims to implement its future plans with respect to the combined company and attract/retain highly talented professionals. The combined company may seek additional financings, investments, and leverage in the future to support its business prospects and portfolio companies.

Industry Context

This merger represents a strategic consolidation within the life science financing sector, aiming to combine the strengths of SWK Holdings and Runway Growth Finance Corp. The focus on a 'Collaborative Approach to Life Science Financing' suggests an intent to enhance capabilities and market reach in providing capital solutions to life science companies, potentially leading to a more robust and diversified platform in a specialized and growing industry.

Legal Proceedings

• Risk of stockholder litigation in connection with the merger, which may result in significant costs of defense and liability.

Stakeholder Impact

• Shareholders (SWK): Will receive a combination of cash and RWAY stock, and the transaction is expected to be a taxable event.
• Shareholders (RWAY): May experience an impact on the depth of trading in RWAY's shares post-closing.
• Bondholders (SWK): RWAY will be required to offer to call SWK's bond at par due to the change of control.
• Management/Employees: Risk of management's attention being diverted from ongoing business operations during the merger process.

Next Steps

• SWK shareholders are urged to read the Combined Proxy Statement and Prospectus, and other documents filed with the SEC, when they become available.
• SWK anticipates releasing its 3Q25 financials in mid-November.
• The merger is expected to close late 4Q25 to early 1Q26.
• RWAY will be required to offer to call SWK's bond at par due to the change of control.

Key Dates

Recommendation

The merger offers a structured exit for SWK shareholders with a combination of cash and stock, providing some liquidity and continued exposure to the life science financing sector through RWAY. The estimated total value per share of ~$17.10 provides a benchmark. However, the market value of the stock component is subject to RWAY's share price fluctuations, and the transaction is expected to be taxable. Given the pending close and the variable nature of the stock component, holding until closer to the closing date to assess RWAY's market performance and final deal terms would be prudent for existing SWK shareholders. For new investors, evaluating the combined entity's prospects and RWAY's standalone valuation would be necessary.

Keywords

SWK Holdings, Runway Growth Finance, Merger, Acquisition, Life Science Financing, SEC Filing, 425, RWAY, Corporate Action, Investment, Financial Services, Healthcare Finance